A Study of Subcutaneous HUMIRA (Adalimumab) Injection to Assess Adverse Events and Change in Disease Activity In Adult Participants With Moderate to Severe Active Crohn's Disease (CD)

Study Purpose

Crohn's disease (CD) is an incurable chronic inflammatory disorder of the gastrointestinal tract. This study will assess how safe and effective Humira (adalimumab) is in treating moderately to severely active CD in China. Adverse events and change in disease activity will be assessed. Humira (adalimumab) is a drug approved for the treatment of Crohn's disease (CD).All study participants will receive Humira as prescribed by their study doctor in accordance with approved local label. Approximately 252 participants will be enrolled in China. Participants will receive subcutaneous HUMIRA (adalimumab) injection as prescribed by their physician according to their routine clinical practice and local label. Participants will be followed for 1 year. There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

Recruitment Criteria

Accepts Healthy Volunteers

Healthy volunteers are participants who do not have a disease or condition, or related conditions or symptoms

Study Type

An interventional clinical study is where participants are assigned to receive one or more interventions (or no intervention) so that researchers can evaluate the effects of the interventions on biomedical or health-related outcomes.

An observational clinical study is where participants identified as belonging to study groups are assessed for biomedical or health outcomes.

Searching Both is inclusive of interventional and observational studies.

Eligible Ages 18 Years and Over
Gender All
More Inclusion & Exclusion Criteria

Inclusion Criteria:

  • - Participants meet the diagnosis of moderate to severe Crohn's disease.
  • - Participants prescribed with Humira, under investigators' sufficient consideration of benefits/ risks per local label.

Exclusion Criteria:

  • - Participants who have any of the contraindications as per adalimumab (Humira) label in China.
  • - Participants who are allergic to any component of adalimumab (Humira).
  • - Participants with active hepatitis B diagnosed.
  • - Participants with severe active infection, or known history of active or latent tuberculosis (TB), or latent TB infection with inadequate treatment.
  • - Participants with cancer diagnosed, excluding also those with non-melanoma skin cancer (NMSC) completely treated, per local label.
  • - Participants with moderate to severe heart failure.
  • - Participants who are unwilling to participate, or not suitable for participation as judged by the investigator at risk of noncompliance to study procedure.
  • - Participants who are enrolled to other interventional studies.
  • - Participants who are prescribed with adalimumab but choose Humira bio-similar in China.

Trial Details

Trial ID:

This trial id was obtained from ClinicalTrials.gov, a service of the U.S. National Institutes of Health, providing information on publicly and privately supported clinical studies of human participants with locations in all 50 States and in 196 countries.


Phase 1: Studies that emphasize safety and how the drug is metabolized and excreted in humans.

Phase 2: Studies that gather preliminary data on effectiveness (whether the drug works in people who have a certain disease or condition) and additional safety data.

Phase 3: Studies that gather more information about safety and effectiveness by studying different populations and different dosages and by using the drug in combination with other drugs.

Phase 4: Studies occurring after FDA has approved a drug for marketing, efficacy, or optimal use.

Lead Sponsor

The sponsor is the organization or person who oversees the clinical study and is responsible for analyzing the study data.

Principal Investigator

The person who is responsible for the scientific and technical direction of the entire clinical study.

Principal Investigator Affiliation AbbVie
Agency Class

Category of organization(s) involved as sponsor (and collaborator) supporting the trial.

Overall Status Recruiting
Countries China

The disease, disorder, syndrome, illness, or injury that is being studied.

Crohn's Disease
Study Website: View Trial Website
Arms & Interventions


: Participants treated with Humira (Adalimumab)

Participants prescribed Humira (adalimumab) for moderately to severely active crohn's disease (CD) in routine clinical practice.


Contact a Trial Team

If you are interested in learning more about this trial, find the trial site nearest to your location and contact the site coordinator via email or phone. We also strongly recommend that you consult with your healthcare provider about the trials that may interest you and refer to our terms of service below.

International Sites

Guangzhou, Guangdong, China




Sun Yat-sen Memorial Hospital of Sun Yat-sen University /ID# 242798

Guangzhou, Guangdong, 510120

Guangzhou, Guangdong, China




Nanfang Hospital of Southern Medical University /ID# 243386

Guangzhou, Guangdong, 510515

Guangzhou, Guangdong, China




The Sixth Affiliated Hosp Sun /ID# 242799

Guangzhou, Guangdong, 510655

Shanghai, Shanghai, China


Not yet recruiting


Ruijin Hospital, Shanghai Jiaotong University School of Medicine /ID# 243213

Shanghai, Shanghai, 200065

Chengdu, Sichuan, China




West China Hospital, Sichuan University /ID# 242804

Chengdu, Sichuan, 610041

Hangzhou, Zhejiang, China




The second Affiliated hospital of Zhejiang University school of Medicine /ID# 242802

Hangzhou, Zhejiang, 310009

Hangzhou, China




Zhejiang Provincial Hospital of Chinese Medicine /ID# 243443

Hangzhou, , 310003